The Gastrointestinal Cancer Channel is supported with funding from Gilead Sciences (Silver) and Revolution Medicines (Silver).
VJOncology is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
ASCO GI 2025 | Pathological response as a predictor for relapse-free survival in early-stage HCC
Antonio D’Alessio, MD, Imperial College London, London, UK, explores the role of pathological response for predicting relapse-free survival in patients with early-stage hepatocellular carcinoma (HCC) treated with neoadjuvant immunotherapy. Pathological response, particularly complete and major pathological responses, was more strongly associated with relapse-free survival than radiological response, and a notable discrepancy between radiological and pathological responses was also reported. These findings highlight the need for standardized criteria to measure pathological response, which will be essential for the design of future clinical trials in this setting. This interview took place at the ASCO GI Cancers Symposium 2025 in San Francisco, CA.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
